Assertio Holdings, Inc. (ASRT)
USD 0.61
(-1.4%)
USD 0.61
(-1.4%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 148.41 Million USD | -21.13% |
| 2022 | 188.18 Million USD | -16.04% |
| 2021 | 224.13 Million USD | -9.54% |
| 2020 | 247.76 Million USD | -47.2% |
| 2019 | 469.21 Million USD | -34.15% |
| 2018 | 712.53 Million USD | -18.02% |
| 2017 | 869.1 Million USD | -10.82% |
| 2016 | 974.54 Million USD | -7.04% |
| 2015 | 1.04 Billion USD | 202.46% |
| 2014 | 346.61 Million USD | -6.63% |
| 2013 | 371.23 Million USD | 543.2% |
| 2012 | 57.71 Million USD | -1.26% |
| 2011 | 58.45 Million USD | -8.56% |
| 2010 | 63.92 Million USD | -15.73% |
| 2009 | 75.85 Million USD | 22.48% |
| 2008 | 61.93 Million USD | 76.32% |
| 2007 | 35.12 Million USD | -56.04% |
| 2006 | 79.9 Million USD | 34.03% |
| 2005 | 59.61 Million USD | 312.14% |
| 2004 | 14.46 Million USD | 10.28% |
| 2003 | 13.11 Million USD | -55.68% |
| 2002 | 29.59 Million USD | 189.45% |
| 2001 | 10.22 Million USD | 146.58% |
| 2000 | 4.14 Million USD | -68.63% |
| 1999 | 13.21 Million USD | 1101.49% |
| 1998 | 1.1 Million USD | 120.0% |
| 1997 | 500 Thousand USD | -28.57% |
| 1996 | 700 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 147.29 Million USD | -0.12% |
| 2024 Q1 | 147.47 Million USD | -0.64% |
| 2023 Q4 | 148.41 Million USD | -20.7% |
| 2023 Q2 | 150.9 Million USD | -7.76% |
| 2023 FY | 148.41 Million USD | -21.13% |
| 2023 Q3 | 187.15 Million USD | 24.02% |
| 2023 Q1 | 163.61 Million USD | -13.06% |
| 2022 Q2 | 193.6 Million USD | -14.81% |
| 2022 Q4 | 188.18 Million USD | -0.13% |
| 2022 FY | 188.18 Million USD | -16.04% |
| 2022 Q3 | 188.42 Million USD | -2.67% |
| 2022 Q1 | 227.27 Million USD | 1.4% |
| 2021 Q3 | 202.44 Million USD | -7.88% |
| 2021 FY | 224.13 Million USD | -9.54% |
| 2021 Q4 | 224.13 Million USD | 10.71% |
| 2021 Q1 | 220.12 Million USD | -11.16% |
| 2021 Q2 | 219.75 Million USD | -0.17% |
| 2020 Q4 | 247.76 Million USD | -3.54% |
| 2020 Q1 | 135.23 Million USD | -71.18% |
| 2020 Q2 | 260.74 Million USD | 92.81% |
| 2020 Q3 | 256.84 Million USD | -1.5% |
| 2020 FY | 247.76 Million USD | -47.2% |
| 2019 Q1 | 674.91 Million USD | -5.28% |
| 2019 Q2 | 615.43 Million USD | -8.81% |
| 2019 Q4 | 469.21 Million USD | -7.71% |
| 2019 Q3 | 508.43 Million USD | -17.39% |
| 2019 FY | 469.21 Million USD | -34.15% |
| 2018 Q1 | 795.98 Million USD | -8.41% |
| 2018 FY | 712.53 Million USD | -18.02% |
| 2018 Q4 | 712.53 Million USD | -3.85% |
| 2018 Q3 | 741.09 Million USD | 2.79% |
| 2018 Q2 | 720.98 Million USD | -9.42% |
| 2017 Q2 | 874.2 Million USD | -7.93% |
| 2017 Q4 | 869.1 Million USD | 0.96% |
| 2017 FY | 869.1 Million USD | -10.82% |
| 2017 Q1 | 949.5 Million USD | -2.57% |
| 2017 Q3 | 860.86 Million USD | -1.53% |
| 2016 Q4 | 974.54 Million USD | 1.63% |
| 2016 Q3 | 958.95 Million USD | 1.05% |
| 2016 FY | 974.54 Million USD | -7.04% |
| 2016 Q1 | 1.03 Billion USD | -1.19% |
| 2016 Q2 | 948.97 Million USD | -8.39% |
| 2015 Q4 | 1.04 Billion USD | 2.69% |
| 2015 Q3 | 1.02 Billion USD | 4.53% |
| 2015 Q2 | 976.66 Million USD | 183.62% |
| 2015 Q1 | 344.35 Million USD | -0.65% |
| 2015 FY | 1.04 Billion USD | 202.46% |
| 2014 Q1 | 308.35 Million USD | -16.94% |
| 2014 Q2 | 279.15 Million USD | -9.47% |
| 2014 Q4 | 346.61 Million USD | -27.63% |
| 2014 FY | 346.61 Million USD | -6.63% |
| 2014 Q3 | 478.96 Million USD | 71.58% |
| 2013 Q1 | 54.97 Million USD | -4.76% |
| 2013 Q2 | 51.04 Million USD | -7.14% |
| 2013 Q3 | 64.53 Million USD | 26.41% |
| 2013 Q4 | 371.23 Million USD | 475.28% |
| 2013 FY | 371.23 Million USD | 543.2% |
| 2012 Q2 | 57.7 Million USD | 9.04% |
| 2012 FY | 57.71 Million USD | -1.26% |
| 2012 Q1 | 52.92 Million USD | -9.46% |
| 2012 Q4 | 57.71 Million USD | -2.62% |
| 2012 Q3 | 59.26 Million USD | 2.7% |
| 2011 Q2 | 55.44 Million USD | -1.64% |
| 2011 FY | 58.45 Million USD | -8.56% |
| 2011 Q3 | 53.53 Million USD | -3.43% |
| 2011 Q1 | 56.36 Million USD | -11.82% |
| 2011 Q4 | 58.45 Million USD | 9.18% |
| 2010 FY | 63.92 Million USD | -15.73% |
| 2010 Q4 | 63.92 Million USD | -7.43% |
| 2010 Q2 | 67.59 Million USD | -5.39% |
| 2010 Q3 | 69.05 Million USD | 2.15% |
| 2010 Q1 | 71.45 Million USD | -5.8% |
| 2009 Q4 | 75.85 Million USD | -5.62% |
| 2009 Q1 | 81.83 Million USD | 32.13% |
| 2009 Q3 | 80.37 Million USD | 1.74% |
| 2009 Q2 | 79 Million USD | -3.46% |
| 2009 FY | 75.85 Million USD | 22.48% |
| 2008 Q4 | 61.93 Million USD | 15.52% |
| 2008 Q1 | 35.16 Million USD | 0.11% |
| 2008 FY | 61.93 Million USD | 76.32% |
| 2008 Q2 | 40.48 Million USD | 15.12% |
| 2008 Q3 | 53.61 Million USD | 32.44% |
| 2007 Q4 | 35.12 Million USD | -3.94% |
| 2007 FY | 35.12 Million USD | -56.04% |
| 2007 Q2 | 70.97 Million USD | -4.69% |
| 2007 Q3 | 36.56 Million USD | -48.48% |
| 2007 Q1 | 74.46 Million USD | -6.81% |
| 2006 Q4 | 79.9 Million USD | 15.01% |
| 2006 Q3 | 69.47 Million USD | 15.95% |
| 2006 FY | 79.9 Million USD | 34.03% |
| 2006 Q1 | 60.31 Million USD | 1.16% |
| 2006 Q2 | 59.91 Million USD | -0.65% |
| 2005 Q4 | 59.61 Million USD | -1.53% |
| 2005 Q2 | 5.47 Million USD | -61.73% |
| 2005 Q1 | 14.29 Million USD | -1.17% |
| 2005 FY | 59.61 Million USD | 312.14% |
| 2005 Q3 | 60.54 Million USD | 1006.6% |
| 2004 FY | 14.46 Million USD | 10.28% |
| 2004 Q2 | 14.3 Million USD | 10.26% |
| 2004 Q4 | 14.46 Million USD | 6.54% |
| 2004 Q3 | 13.57 Million USD | -5.08% |
| 2004 Q1 | 12.97 Million USD | -1.09% |
| 2003 Q4 | 13.11 Million USD | -5.68% |
| 2003 Q3 | 13.9 Million USD | -47.98% |
| 2003 Q2 | 26.73 Million USD | -8.22% |
| 2003 Q1 | 29.12 Million USD | -1.58% |
| 2003 FY | 13.11 Million USD | -55.68% |
| 2002 Q2 | 24.47 Million USD | 115.38% |
| 2002 Q3 | 26.92 Million USD | 9.98% |
| 2002 Q4 | 29.59 Million USD | 9.93% |
| 2002 FY | 29.59 Million USD | 189.45% |
| 2002 Q1 | 11.36 Million USD | 11.16% |
| 2001 Q2 | 6.5 Million USD | 17.75% |
| 2001 Q3 | 8.03 Million USD | 23.59% |
| 2001 Q4 | 10.22 Million USD | 27.25% |
| 2001 FY | 10.22 Million USD | 146.58% |
| 2001 Q1 | 5.52 Million USD | 33.16% |
| 2000 Q2 | 2.02 Million USD | 29.85% |
| 2000 Q3 | 2.98 Million USD | 47.65% |
| 2000 Q4 | 4.14 Million USD | 38.84% |
| 2000 FY | 4.14 Million USD | -68.63% |
| 2000 Q1 | 1.55 Million USD | -88.21% |
| 1999 Q1 | 800 Thousand USD | -27.27% |
| 1999 Q3 | 1.3 Million USD | 30.0% |
| 1999 Q4 | 13.21 Million USD | 916.65% |
| 1999 FY | 13.21 Million USD | 1101.49% |
| 1999 Q2 | 1 Million USD | 25.0% |
| 1998 FY | 1.1 Million USD | 120.0% |
| 1998 Q1 | 300 Thousand USD | -40.0% |
| 1998 Q2 | 400 Thousand USD | 33.33% |
| 1998 Q4 | 1.1 Million USD | 266.67% |
| 1998 Q3 | 300 Thousand USD | -25.0% |
| 1997 Q3 | 2.3 Million USD | 0.0% |
| 1997 Q4 | 500 Thousand USD | -78.26% |
| 1997 FY | 500 Thousand USD | -28.57% |
| 1996 FY | 700 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 84.342% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1513.812% |
| Embecta Corp. | 2.03 Billion USD | 92.711% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 78.926% |
| PainReform Ltd. | 2.69 Million USD | -5415.273% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2317.356% |
| SCYNEXIS, Inc. | 55.45 Million USD | -167.657% |
| Journey Medical Corporation | 56.49 Million USD | -162.688% |
| Safety Shot Inc | 3.89 Million USD | -3713.318% |
| Alpha Teknova, Inc. | 38.55 Million USD | -284.986% |
| Bright Green Corporation | 6.43 Million USD | -2205.276% |
| Procaps Group, S.A. | 462.06 Million USD | 67.88% |
| Alvotech | 1.88 Billion USD | 92.116% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 68.534% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 9.45% |
| Cosmos Health Inc. | 30.25 Million USD | -390.59% |
| Dynavax Technologies Corporation | 375.02 Million USD | 60.425% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 77.54% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -8.435% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2317.356% |
| Theratechnologies Inc. | 98.63 Million USD | -50.464% |
| Harrow Health, Inc. | 241.75 Million USD | 38.608% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1595.021% |
| Biofrontera Inc. | 23.13 Million USD | -541.411% |
| DURECT Corporation | 30.4 Million USD | -388.114% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 69.553% |
| Cronos Group Inc. | 43.73 Million USD | -239.345% |
| OptiNose, Inc. | 194.33 Million USD | 23.629% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 81.842% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -206.36% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -607.48% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 18.166% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -3834.537% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -182.61% |
| Radius Health, Inc. | 804.29 Million USD | 81.547% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -979.049% |
| ProPhase Labs, Inc. | 42.54 Million USD | -248.853% |
| Phibro Animal Health Corporation | 725.54 Million USD | 79.544% |
| Procaps Group S.A. | 462.06 Million USD | 67.88% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -958.451% |
| Viatris Inc. | 27.21 Billion USD | 99.455% |
| Rockwell Medical, Inc. | 30.88 Million USD | -380.591% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -64.215% |
| SIGA Technologies, Inc. | 57.97 Million USD | -155.99% |
| Tilray Brands, Inc. | 892.11 Million USD | 83.364% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 32.477% |
| Shineco, Inc. | 47.6 Million USD | -211.787% |
| PetIQ, Inc. | 645.22 Million USD | 76.998% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -67511.793% |
| Incannex Healthcare Limited | 5.83 Million USD | -2445.729% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 85.441% |
| Alimera Sciences, Inc. | 107.35 Million USD | -38.249% |
| Silver Spike Investment Corp. | 3 Million USD | -4831.041% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -7727.993% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -596.273% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -2012.383% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1648.018% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 14.402% |
| Hempacco Co., Inc. | 18.82 Million USD | -688.507% |
| Talphera, Inc. | 6.29 Million USD | -2259.555% |
| Alvotech | 1.88 Billion USD | 92.116% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 14.012% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 82.231% |
| Currenc Group, Inc. | 177.67 Million USD | 16.468% |
| Kamada Ltd. | 109.96 Million USD | -34.963% |
| Indivior PLC | 1.95 Billion USD | 92.394% |
| Evoke Pharma, Inc. | 9.64 Million USD | -1438.295% |
| Flora Growth Corp. | 17.22 Million USD | -761.781% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1648.018% |
| Evolus, Inc. | 209.68 Million USD | 29.22% |
| HUTCHMED (China) Limited | 536.38 Million USD | 72.33% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 83.009% |
| Akanda Corp. | 12.66 Million USD | -1071.5% |